[August 29, 2016] |
|
IMS Health and Quintiles Announce Key Officers for Merged Company
IMS Health Holdings, Inc. (NYSE:IMS) and Quintiles Transnational
Holdings Inc. (NYSE:Q) today announced key senior management roles in
the future Quintiles IMS corporate leadership team, subject to the
completion of the merger.
Senior functional leaders reporting to Chairman and Chief Executive
Officer Ari Bousbib will include Michael McDonnell, EVP and Chief
Financial Officer; James Erlinger, EVP and General Counsel; and Trudy
Stein, EVP and Chief Human Resources Officer.
Global business leaders reporting to Mr. Bousbib will include, for the
clinical research business, Tom Pike, Vice Chairman and President,
Research & Development Solutions; and for the commercial business, Kevin
Knightly, President, Information and Technology Solutions (News - Alert); José Luis
Fernández, President, Global Services; Jon Resnick, President,
Real-World Insights; and Scott Evangelista, President, Contract Sales
Organization.
"I am proud to be part of a leadership team with deep industry
knowledge, a proven track record of success and a commitment to
transforming healthcare for the better," said Ari Bousbib. "That
commitment extends across the 50,000 talented professionals who will
soon become part of one global team. Together, we are making excellent
progress on our integration planning and are confident that we will be
ready for a strong start on day one of the merger."
About IMS Health
IMS Health (NYSE:IMS) is a leading global information and technology
services company providing clients in the healthcare industry with
end-to-end solutions to measure and improve their performance. Our 7,000
services experts connect configurable SaaS (News - Alert) applications to 15+ petabytes
of complex healthcare data in the IMS One™ cloud platform, delivering
unique insights into diseases, treatments, costs and outcomes. The
company's 15,000 employees blend global consistency and local market
knowledge across 100 countries to help clients run their operations more
efficiently. Customers include pharmaceutical, consumer health and
medical device manufacturers and distributors, providers, payers,
government agencies, policymakers, researchers and the financial
community.
As a global leader in protecting individual patient privacy, IMS Health
uses anonymous healthcare data to deliver critical, real-world disease
and treatment insights. These insights help biotech and pharmaceutical
companies, medical researchers, government agencies, payers and other
healthcare stakeholders to identify unmet treatment needs and understand
the effectiveness and value of pharmaceutical products in improving
overall health outcomes. Additional information is available at www.imshealth.com.
About Quintiles
Quintiles (NYSE:Q) helps biopharma and other healthcare companies
improve their probability of success by connecting insights from our
deep scientific, therapeutic and analytics expertise with superior
delivery for better outcomes. From advisory through operations,
Quintiles is the world's largest provider of product development and
integrated healthcare services, including commercial and observational
solutions. Conducting operations in approximately 100 countries,
Quintiles is a member of the Fortune 500 and has been named to Fortune's
list of the "World's Most Admired Companies." To learn more, visit www.quintiles.com.
Important Information about the Transaction and Where to Find It
In connection with the proposed transaction, IMS Health and Quintiles
have filed documents with the SEC (News - Alert), including the filing by Quintiles of
a registration statement on Form S-4 that includes a joint proxy
statement that also constitutes a prospectus of Quintiles. The
registration statement, as amended, was declared effective on August 15,
2016 by the SEC. Quintiles filed the definitive joint proxy
statement/prospectus with the SEC on August 16, 2016. On August 19,
2016, each of IMS Health and Quintiles mailed that document to their
respective shareholders and may also file other documents with the SEC
regarding the proposed transaction. This document is not a substitute
for the joint proxy statement/prospectus or registration statement or
any other document which IMS Health or Quintiles may file with the SEC. Investors
and security holders of IMS Health and Quintiles are urged to read the
registration statement, the joint proxy statement/prospectus and any
other relevant documents, as well as any amendments or supplements to
these documents, carefully and in their entirety when they become
available because they will contain important information. Investors
and security holders may obtain free copies of the registration
statement and the joint proxy statement/prospectus and other documents
filed with the SEC by IMS Health and Quintiles through the web site
maintained by the SEC at www.sec.gov
or by contacting the investor relations department of IMS Health or
Quintiles at the following:
|
|
|
|
|
|
|
IMS Health
|
|
|
|
|
|
Quintiles
|
[email protected]
|
|
|
|
|
|
[email protected]
|
+1.203.448.4600
|
|
|
|
|
|
+1.919.998.2590
|
Investor Relations
|
|
|
|
|
|
4820 Emperor Boulevard
|
83 Wooster Heights RD
|
|
|
|
|
|
PO Box (News - Alert) 13979
|
Danbury, CT, 06810
|
|
|
|
|
|
Durham, North Carolina 27703
|
|
|
|
|
|
|
|
No Offer or Solicitation
This communication is not intended to and shall not constitute an offer
to sell or the solicitation of an offer to sell or the solicitation of
an offer to buy any securities or a solicitation of any vote of
approval, nor shall there be any sale of securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction. No offer of securities shall be made except by means of a
prospectus meeting the requirements of Section 10 of the Securities Act
of 1933, as amended.
Click
here to subscribe to Mobile Alerts for Quintiles.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160829005299/en/
[ Back To Mobile World Congress's Homepage ]
|